114 related articles for article (PubMed ID: 6745306)
21. Systemic exposure of vinpocetine in pregnant Sprague Dawley rats following repeated oral exposure: An investigation of fetal transfer.
Waidyanatha S; Toy H; South N; Gibbs S; Mutlu E; Burback B; McIntyre BS; Catlin N
Toxicol Appl Pharmacol; 2018 Jan; 338():83-92. PubMed ID: 29155086
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics of flupirtine in elderly volunteers and in patients with moderate renal impairment.
Abrams SM; Baker LR; Crome P; White AS; Johnston A; Ankier SI; Warrington SJ; Turner P; Niebch G
Postgrad Med J; 1988 May; 64(751):361-3. PubMed ID: 3200777
[TBL] [Abstract][Full Text] [Related]
23. Determination of vinpocetine and its primary metabolite, apovincaminic acid, in rat plasma by liquid chromatography-tandem mass spectrometry.
Xia HM; Su LN; Guo JW; Liu GM; Pang ZQ; Jiang XG; Chen J
J Chromatogr B Analyt Technol Biomed Life Sci; 2010 Jul; 878(22):1959-66. PubMed ID: 20561830
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics of glucarpidase in subjects with normal and impaired renal function.
Phillips M; Smith W; Balan G; Ward S
J Clin Pharmacol; 2008 Mar; 48(3):279-84. PubMed ID: 18192538
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics of enprofylline in patients with impaired renal function after a single intravenous dose.
Lunell E; Borgå O; Larsson R
Eur J Clin Pharmacol; 1984; 26(1):87-93. PubMed ID: 6714295
[TBL] [Abstract][Full Text] [Related]
26. Synthesis and biological evaluation of Vinpocetine derivatives.
Pan BW; Shi Y; Li WC; Wang Q; Pan M; Wu Q; Fu HZ
Bioorg Med Chem Lett; 2020 Jan; 30(2):126472. PubMed ID: 31859156
[TBL] [Abstract][Full Text] [Related]
27. Determination of apovincaminic acid in serum by means of high-performance liquid chromatography.
Kraus G; Schulz HU; Lohmann A
J Chromatogr; 1992 Jan; 573(2):323-7. PubMed ID: 1601968
[TBL] [Abstract][Full Text] [Related]
28. Effect of renal impairment on the pharmacokinetics of levomilnacipran following a single oral dose of levomilnacipran extended-release capsule in humans.
Chen L; Greenberg WM; Brand-Schieber E; Wangsa J; Periclou A; Ghahramani P
Drug Des Devel Ther; 2015; 9():3293-300. PubMed ID: 26150701
[TBL] [Abstract][Full Text] [Related]
29. [Pharmacokinetics and disposition of vinpocetine in rats].
Yao JH; Su CY; Chu XY
Yao Xue Xue Bao; 1994; 29(2):81-5. PubMed ID: 8042515
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics of vinpocetine and its metabolite, apovincaminic acid, in plasma and cerebrospinal fluid after intravenous infusion.
Polgár M; Vereczkey L; Nyáry I
J Pharm Biomed Anal; 1985; 3(2):131-9. PubMed ID: 16867695
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics of naproxen in subjects with normal and impaired renal function.
Anttila M; Haataja M; Kasanen A
Eur J Clin Pharmacol; 1980 Oct; 18(3):263-8. PubMed ID: 7439246
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics of tocainide in patients with combined hepatic and renal dysfunction.
Oltmanns D; Pottage A; Endell W
Eur J Clin Pharmacol; 1983; 25(6):787-90. PubMed ID: 6420165
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics of cefpiramide in healthy volunteers, patients with various degrees of renal dysfunction, and patients on hemodialysis.
Ohkawa M; Tokunaga S; Sugata T; Shimamura M; Okasho A; Hirano S; Matsui H
Chemotherapy; 1989; 35(6):416-22. PubMed ID: 2612231
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics in renally impaired subjects of NXY-059, a nitrone-based, free-radical trapping agent developed for the treatment of acute stroke.
Strid S; Borgå O; Edenius C; Jostell KG; Odergren T; Weil A
Eur J Clin Pharmacol; 2002 Sep; 58(6):409-15. PubMed ID: 12242600
[TBL] [Abstract][Full Text] [Related]
35. Effect of renal impairment on the pharmacokinetics of cilostazol and its metabolites.
Mallikaarjun S; Forbes WP; Bramer SL
Clin Pharmacokinet; 1999; 37 Suppl 2():33-40. PubMed ID: 10702885
[TBL] [Abstract][Full Text] [Related]
36. [Human positron emission tomography with oral 11C-vinpocetine].
Vas A; Christer H; Sóvágó J; Johan S; Cselényi Z; Kiss B; Kárpáti E; Lars F; Gulyás B
Orv Hetil; 2003 Nov; 144(46):2271-6. PubMed ID: 14702922
[TBL] [Abstract][Full Text] [Related]
37. Vinpocetine, cognition, and epilepsy.
Meador KJ; Leeman-Markowski B; Medina AE; Illamola SM; Seliger J; Novak G; Lin C; Ivanisevic M; Razavi B; Marino S; Boyd A; Loring DW
Epilepsy Behav; 2021 Jun; 119():107988. PubMed ID: 33957389
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics of ceftazidime in normal and impaired renal function.
Höffler D; Koeppe P; Williams KJ
Arzneimittelforschung; 1984; 34(1):72-6. PubMed ID: 6367755
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetics of ceftezole in patients with normal and impaired renal function.
Ohkawa M; Kuroda K
Chemotherapy; 1980; 26(4):242-7. PubMed ID: 7389424
[TBL] [Abstract][Full Text] [Related]
40. Metoclopramide kinetics in patients with impaired renal function and clearance by hemodialysis.
Lehmann CR; Heironimus JD; Collins CB; O'Neil TJ; Pierson WP; Crowe JT; Melikian AP; Wright GJ
Clin Pharmacol Ther; 1985 Mar; 37(3):284-9. PubMed ID: 3971652
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
